Advanced Lung Cancer Inflammation index: a prognostic score in patients with metastatic non-small cell lung cancer

##plugins.themes.academic_pro.article.sidebar##

Published May 3, 2018
Download
pdf
Vol. 95 No. 11 (2017): Issue Nov 2017

##plugins.themes.academic_pro.article.main##

Saoussen Bacha
Améni sghaier
Sonia Habibech
Sana Cheikhrouhou
Hager Racil
Naouel Chaouch
Abdellatif Chabbou
Mohamed Lamine Megdiche

Abstract

Introduction: Recent studies have identified that inflammation had a significant association with cancer development and progression. The aim of this study was to explore the relationship between ALI score and prognosis of metastatic non-small cell lung cancer (NSCLC).
Methods: we conducted a retrospective study of 41 patients with metastatic NSCLC diagnosed between January2010 and January2012. ALI was calculated as body mass index x serum albumin/neutrophil to lymphocyte ratio. Patients were divided as low inflammation (ALI≥23.2) and high inflammation (ALI<23.2) groups.
Results: Mean age was 56.3 years, 100% were male, and 49% had adenocarcinoma. The overall survival was 8.9months. Median ALI was 23.2. The median overall survival was 6.7 months and 11.3 months respectively in patients with ALI score<23.2 and ≥23.2 (p=0.043). On multivariate analysis, ALI score < 23.2 remained significantly associated with worse outcome.
Conclusion: Lower ALI (<23.2) was significantly associated with worse overall survival in metastatic NSCLC. The assessment of the ALI is inexpensive and widely available; it could help in identifying patients with poor prognosis in clinical routine practice.

Keywords:

non-small cell lung cancer; prognosis; inflammation; survival

##plugins.themes.academic_pro.article.details##

References

  1. Locatelli-Sanchez M, Couraud S, Souquet PJ. Epidémiologie du cancer bronchique: données actuelles. Rev Mal Respir2015;7:285-9.
  2. Missaoui N, Hmissa S, Landolsi H, Korbi S, Joma W, Anjorin A, et al. Lung cancer in central Tunisia: epidemiology and clinicopathological features. Asian Pac J Cancer Prev 2011;12:2305-9.
  3. Stinchcombe TE, Socinski MA. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J ThoracOncol 2009;4:243-50.
  4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The Lancet 2001;357:539-45.
  5. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link? BiochemPharmacol 2006;72:1605-21.
  6. Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park J-H, et al. Circulating Inflammation Markers and Prospective Risk for Lung Cancer. J Natl Cancer Inst 2013;105:1871-80.
  7. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298‑306.
  8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436‑44.
  9. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. CurrOncol Rep 2002;4:250‑5.
  10. Jafri SH, Shi R, Mills G. Advanced lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 2013;13:158.
  11. Park YH, Yi HG, Lee MH, Kim CS, Lim JH. Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy.ActaHaemtol2017; 137(2):76-85.
  12. Kim EY, Kim N, Kim YS, Seo JY, Park I, Ahn HK et al. Prognostic Significance of Modified Advanced Lung Cancer Inflammation Index (ALI) in Patients with small cell lung cancer Comparison with Original ALI. PLoS ONE 2016;11(10): e0164056.
  13. He X, Zhou T, Yang Y, Hong S, Zhan J, Hu Z et al. Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small cell lung cancer. Clin Lung Cancer 2015;16:165-71.
  14. Feng JF, Huang Y, Chen QX. A new inflammation index is useful for patients with esophageal squamous cell carcinoma. OncoTargetsTher 2014;7:1811-5.
  15. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004;90:1704-6.
  16. Cuyun Carter G, Barrett A, Kaye J, Liepa A, Winfree K, John W. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res 2014;6: 437-49.
  17. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028‑30.
  18. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. ClinSci 1999;97:215‑23.
  19. Long CL. Energy balance and carbohydrate metabolism in infection and sepsis. Am J ClinNutr 1977;30:1301‑10.
  20. Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J ClinOncol 1995;13:2600‑5.
  21. Umihanic S, Umihanic S, Jamakosmanovic S, Brkic S, Osmic M, Dedic S, et al. Glasgow Prognostic Score in Patients Receiving Chemotherapy for Non-small-cell Lung Cancer in Stages IIIb and IV. Med Arch 2014;68:83.
  22. Gioulbasanis I, Baracos VE, Giannousi Z, Xyrafas A, Martin L, Georgoulias V, et al. Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Ann Oncol 2011;22:835‑41.
  23. Sarhill N. Assessment of nutritional status and fluid deficits in advanced cancer. Am J HospPalliat Med 2003;20:465‑73.
  24. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J 2010;9:69.
  25. Epstein FH, Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448‑54.
  26. Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, et al. Systemic Inflammation, Nutritional Status and Tumor Immune Microenvironment Determine Outcome of Resected Non-Small Cell Lung Cancer. PloS One 2014;9:106914.
  27. Chandra RK. Nutrition and the immune system from birth to old age. Eur J ClinNutr 2002;56(3 Suppl):73‑6.
  28. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Rates in Patients with Non-Small Cell Lung Cancer Associated with Treatment Response and Prognosis? Asian Pac J Cancer Prev 2013;14:5237‑42.
  29. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer ImmunolImmunother 2012;62:471‑9.
  30. Kacan T, Babacan NA, Seker M, Yucel B, Bahceci A, Eren AA, et al. Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non-Small Cell Lung Cancers? Asian Pac J Cancer Prev 2014;15:2089‑94.
  31. Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, et al. Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: J ThoracOncol 2015;10:280‑5.
  32. Gu X-B, Tian T, Tian X-J, Zhang X-J. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep; 5:12493.
  33. Aliustaoglu M, Bilici A, Ustaalioglu BBO, Konya V, Gucun M, Seker M, et al. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 2009;27:1060‑5.
  34. An X, Ding P-R, Li Y-H, Wang F-H, Shi Y-X, Wang Z-Q, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010;15:516‑22.
  35. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012;48:202‑8.
  36. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011;104:1288‑95.
  37. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979‑85.
  38. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of Tumor-Associated Neutrophil (TAN) Phenotype by TGF-β: «N1» versus «N2» TAN. Cancer Cell 2009;16:183‑94.
  39. Jablonska J, Wu C-F, Andzinski L, Leschner S, Weiss S. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β. Int J Cancer 2014;134:1346‑58.
  40. Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest 2013;123:3446‑58.
  41. Braumüller H, Wieder T, Brenner E, Abmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494:361-5.